Sarcomas are mesenchymal tumors characterized by blocked differentiation process. In Ewing sarcoma (EWS) both CD99 and EWS-FLI1 concur to oncogenesis and inhibition of differentiation. Here, we demonstrate that uncoupling CD99 from EWS-FLI1 by silencing the former, nuclear factor-κB (NF-κB) signaling is inhibited and the neural differentiation program is re-established. NF-κB inhibition passes through miR-34a-mediated repression of Notch pathway. CD99 counteracts EWS-FLI1 in controlling NF-κB signaling through the miR-34a, which is increased and secreted into exosomes released by CD99-silenced EWS cells. Delivery of exosomes from CD99-silenced cells was sufficient to induce neural differentiation in recipient EWS cells through miR-34a inhibition of Notch-NF-κB signaling. Notably, even the partial delivery of CD99 small interfering RNA may have a broad effect on the entire tumor cell population owing to the spread operated by their miR-34a-enriched exosomes, a feature opening to a new therapeutic option.
INTRODUCTION
Ewing sarcoma (EWS) is the second most common type of primary bone tumor and mainly affects children and adolescents. It is an aggressive, poorly differentiated tumor, with elevated tendency to give lung and/or bone metastases. Despite the use of intensive, multimodality therapy, 1 the prognosis of patients with metastatic EWS remains grim (survival o40% even with intensive chemotherapy) 2 and few treatments can be offered to those who relapse after first-line therapies. Even for children who are cured, the long-term morbidity of cytotoxic treatment is substantial, 3 indicating the need of new therapeutic strategies for this disease.
From a genetic point of view, EWS is characterized by highly recurrent translocations involving ETS transcription factors, with EWS-FLI1 and EWS-ERG being the most common. 4 ,5 EWS-FLI1 functions as an aberrant transcription factor that regulates crucial processes such as cell growth, apoptosis and differentiation through induction or repression of specific target genes and it is the oncogenetic driver of EWS. 6 Forced expression of EWS-FLI1 in human mesenchymal stem cells, the closest EWS-related normal cell type, was demonstrated to be sufficient to transform cells and induce a gene expression profile similar to that observed in EWS cells, 7 whereas deprivation of EWS-FLI1 in EWS cells resulted in a gene expression signature that overlapped with mesenchymal progenitor cells 8 and decreased in vivo and in vitro tumor growth. 9, 10 The genomic landscape of EWS, which has been recently explored by three different groups through multiple nextgeneration sequencing methods [11] [12] [13] clearly showed that the somatic mutation rate in EWS is low. Apart from the already known copy-number gains in whole chromosomes 8, 12 and the q arm of chr 1 and the loss in the long arm of chr 16 and the CDKN2A locus on chr 9p, 14, 15 no recurrent somatic mutations have been reported in EWS, with the notable exceptions of TP53 (5-20%) and the cohesin complex family member STAG2 (15-21%). [11] [12] [13] Although these alterations are reported to influence patient's prognosis and serve as potential biomarkers for patient's risk stratification, 11, 16 their therapeutic value is limited. The sequencing of EWS genomes further sustains the pivotal role of EWS-FLI1 in the pathogenesis and progression of EWS and points to EWS-FLI1 as the best target. Nevertheless, EWS-FLI1 provides necessary but insufficient condition for tumor transformation requiring a permissive cellular background. Although the list of critical adjuvant transforming factors is still incomplete, disruption of the p53 and RB pathways, the presence of intact insulin-like growth factor signaling and of CD99 have been confirmed. [17] [18] [19] CD99 is a cell surface molecule of 32 kDa 20 involved in crucial biological processes such as migration, cell death and differentiation. [21] [22] [23] CD99 is constantly present at high levels in EWS cells and its detection is routinely used for differential diagnosis. The EWS-FLI1 oncogenic activity 6 is facilitated by CD99, 19 and, consistently, EWS-FLI1 maintains high levels of CD99 expression 19, [24] [25] [26] either directly through binding of CD99 promoter 19 or indirectly through miRNA regulation. 27 CD99 knockdown in EWS cells induces terminal neural differentiation and reduces tumor growth and bone metastasis upon transplantation into immunodeficient mice, 19 supporting a central role for CD99 in the pathogenesis of EWS. In this article, we analyze the relationship between CD99 and EWS-FLI1 in an effort to identify the mechanisms that reversing the tumorigenicity of EWS cells would take them back to the road of normal differentiation. Differently from other solid tumors, sarcomas could be reprogrammed to resume normal differentiation, 28 an intriguing approach that offers new options for the treatment of these tumors. Both CD99 and EWS-FLI1 appear to impact on EWS cell differentiation with opposite effects: while EWS-FLI1 may induce neural differentiation, CD99 prevents it. 19 The net effect is a cell that exhibits some neural features while maintaining cell growth capacity. Additional activation or repression of other molecular pathways would be necessary to alter this equilibrium in favor of the achievement of a complete neuronal differentiation process. With this study, we aimed at the identification of the missing molecules, providing mechanistic proof of principle for potential novel therapeutic intervention in EWS.
RESULTS
CD99 affects EWS cell differentiation through NF-κB transcriptional activity Deprivation of CD99 drives EWS cells toward neural differentiation 19 (Supplementary Figure 1) . To understand the mechanism behind neural differentiation, we studied the transcriptional activity of five transcription factors (SRE, E2F, CREB, NF-κB (nuclear factor-κB) and AP1) involved in cell growth and differentiation. Using luciferase reporter assay, upon CD99 silencing we observed a significant downregulation of NF-κB activity (Figure 1a ), but not of SRE, E2F, CREB and AP1 (Supplementary Figure 2) . In general, the activation of NF-κB occurs when NF-κB members are transported from the cytoplasm to the nucleus upon uncoupling NF-κB factors from inhibitory IκB proteins. 29 Optimal induction of NF-κB-target genes also requires phosphorylation of NF-κB proteins, such as p65, whose phosphorylation at Ser536 enhances its transactivation potential. 30 Accordingly, knockdown of CD99 reduced the levels of Ser536 phosphorylation in EWS cells (Figure 1b ). To establish a functional relationship between NF-κB activity and EWS cell differentiation, we used a gain-and loss-of-function approach. Overexpression of NF-κB in TC-CD99-shRNA #1 and CAR-CD99-shRNA #1 cells through transient transfection of the pCMVp65 plasmid induced a loss of the neural differentiation, shifting the expression of β-III Tubulin and neurofilament-H (NF-H) back to baseline (Figure 1c) . Conversely, stable silencing of NF-κBp65 in the parental, CD99-high-expressing TC-71 cell line (Supplementary Figure 3A) induced neural differentiation (Figure 1d ). Taken together, these evidences indicate that the prodifferentiative effect due to CD99 silencing occurs via inhibition of NF-κB activity in EWS cells.
CD99 antagonizes EWS-FLI1 in controlling NF-κB-mediated EWS differentiation Previous studies have suggested that EWS-FLI1 induces a neural phenotype in a variety of cellular contexts. 25, 31, 32 EWS-FLI1 also upregulates CD99 expression, 17, 19, 25, 27 which in turn antagonizes EWS-FLI1-induced neural differentiation. 19 We examined the functional interplay between CD99 and EWS-FLI1 with respect to the neural differentiation of EWS cells and the modulation of NF-κB transcriptional activity. We took advantage of the ASP14 cell line, harnessed for the doxycyclin-inducible shRNA (short hairpin RNA) targeting of EWS-FLI1. In these cells, induced silencing of EWS-FLI1 resulted in a strong activation of NF-κB (Figure 2a) , without significantly changing the expression of the neural marker β-III Tubulin (Figure 2b ). When CD99 was simultaneously silenced (Supplementary Figure 3B) , the above increase of NF-κB activity was completely lost (Figure 2a) . The parallel analysis of neural differentiation showed that ASP14 cells deprived of CD99 but not of EWS-FLI1 displayed a significant increase of β-III Tubulin immunostaining, an effect that was still maintained when EWS-FLI1 was concomitantly silenced (Figure 2b ). The same result was obtained with the TC-71 cell line (Figures 2a and b) . Transient silencing of EWS-FLI1 in TC-71 cells (Supplementary Figure 3B) induced upregulation of NF-κB transcriptional activity that did not occur in case CD99 was also silenced with NF-κB remaining at baseline level (Figure 2a) . In silenced CD99 cells with low NF-κB transcriptional activity, the expression of β-III Tubulin was increased independently of EWS-FLI1 expression (Figure 2b ), suggesting that CD99 efficiently contrasts EWS-FLI1 in term of neuronal differentiation. To confirm this finding, we used the C3H1OT1/2 murine mesenchymal multipotent cell line that loses the ability to differentiate into the osteoblastic and adipocytic, while gains neural phenotype and tumorigenic properties upon EWS-FLI1 transfection 33 (Supplementary Figure 3C) . In this cell line, CD99 cDNA transfection repressed the feature of neural differentiation induced by EWS-FLI1. 19 Here we show that the forced expression of CD99 enhances NF-κB activity, in parallel with reduction of β-III Tubulin and NF-H expression (Figure 2c ). On these evidences, we propose that CD99 expression in EWS cells sustains NF-κB transcriptional activity, prevents terminal neural differentiation and counteracts the effects of EWS-FLI1.
CD99 regulation of NF-κB transcriptional activity is through miR-34a-induced control of Notch pathway CD99 does not regulate NF-κB either at mRNA or protein levels ( Figure 1b and Supplementary Figure 4a ), but rather its signaling machinery. Here we showed that treatment of the EWS cell lines with tumor necrosis factor-α (TNFα), a prototype inducer of NF-κB signaling, 34 translocated NF-κBp65 in the nucleus and induced NF-κB-dependent transcription, regardless of whether CD99 was either present or absent (Supplementary Figures 4B and C) . This suggests that CD99 regulation is outside the NF-κB signaling machinery responding to TNFα and may be independent of IκBα regulation. 35 Thus, we evaluated the involvement of other, still incompletely understood, mechanisms that may act as alternative transcriptional regulators of NF-κB. 36 In particular, we investigated the role of Notch, a developmental pathway involved in the regulation of cell fate. NF-κB and Notch reciprocal modulation has been described in specific cellular contexts, such as during T-cell, neuron and osteoblast differentiation, and in pancreatic cancer cells. 37, 38 In our experimental model, CD99-shRNA EWS cells showed lower levels of Notch receptor and ligand proteins compared with parental cells and reduced expression of the Notch-target gene HEY-1. Conversely, the forced expression of CD99 in C3H1OT1/2 EF cells increased the protein levels of the Notch ligand Delta and Notch 1 receptor (Figure 3a) . Inhibition of Notch pathway in parental EWS cells, by treatment with the γ- (Figure 3b ), decreased the levels of NF-κBp65 luciferase activity ( Figure 3b ) and concomitantly increased the expression of β-III Tubulin (Figure 3c ). This indicates that Notch inhibition is associated with the NF-κB-mediated neural differentiation of EWS cells. We then examined whether the miR-34a, which regulates the Notch pathway and has a role in EWS malignancy, 39, 40 could be the molecule bridging CD99 with Notch and NF-κB. According to our hypothesis, miR-34a was significantly upregulated in CD99-silenced EWS cells (Figure 4a Figure 3A) in TC-71 induces an upregulation of β-III Tubulin and NF-H. Digital images were taken under identical conditions, at the same time and using the same image analysis software as described in the Materials and Methods section. Scale bars: 50 μm. Bar graphs represent the fold increase of NF-κBp65 activity of three independent experiments performed in triplicate (mean ± s.e.m., **Po0.01 Student's t-test). Percentages of β-III Tubulin-and NF-H-positive cells are reported.
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CD99 is released via exosomes inducing differentiation of EWS recipient cells by recapitulating miR-34a-Notch dependent regulation of NF-κB activity CD99 was found to be secreted by EWS cells (data not shown), shuttled by exosomes (Figure 5a ). Exosomes were purified from either parental or CD99-shRNA EWS cell lines and characterized by western blot for the enrichment of proteins commonly used as microvesicle markers, such as RAB5B, CD63 and CD81 (Figure 5a ). In addition, the expression analysis of the CD99-shRNA-derived exosomal cargo showed, besides the obvious lack of CD99 (Figure 5a ), a higher level of miR-34a coincident with Notch 1 and Notch 3 repression (Figure 5b ). We then evaluated whether Figure 3C) . Forced expression of CD99 in C3H1OT1/2 EF increased NF-κB transactivation (bars graph represents mean ± s.e.m. of two independent experiments performed in triplicate, *Po 0.05 Student's t-test) and repressed neural differentiation, as shown by β-III Tubulin and NF-H immunostaining. Digital images were taken under identical conditions, at the same time and using the same image analysis software as described in the Materials and Methods section. Scale bars: 50 μm. Percentages of β-III Tubulin-and NF-H-positive cells are reported.
the uptake of exosomes from CD99-silenced cells by parental EWS cells might be sufficient to mimic CD99 silencing in virtue of miR-34a content. Evidence of effective exosomes internalization was indirectly obtained by revealing CD99 expression variation in CD99-shRNA cells after exposure to exosomes derived from parental and silenced cells (Supplementary Figure 3D) . The neural differentiation of EWS parental cells induced by the internalization of exosomes lacking CD99 was detected as increase of β-III Tubulin (Figure 5c ). Concordantly, this effect mimics that of miR-34a transfer, such as repression of Notch 1 and 3 and in turn downregulation of NF-κB transcriptional activity (Figure 5d and data not shown). These findings support the notion that exosomes can convey the same prodifferentiative signals in EWS recipient cells as induced by stable silencing of CD99.
DISCUSSION
NF-κB has a pivotal role in inflammation, immunity, development and cancer. Indeed, NF-κB transcription factors control the expression of genes active in cell proliferation, survival, differentiation, invasion, angiogenesis and metastasis and it is constitutively active in most tumor cells. 36, 41 Of interest here is the role of the NF-κB pathway in the differentiation of normal and malignant cells of the central nervous system, myeloid lineage and osteoclasts. [42] [43] [44] [45] [46] EWS cells have low NF-κB activity. 47 Nevertheless, its inhibition sensitized EWS cells to TNFα-induced killing 48, 49 and reduced their ability to form tumors when transplanted into immunodeficient mice. 50 Inhibition of NF-κB was also shown to enhance the apoptotic activity of histone deacetylase inhibitors 51 and of nutlin-3, 52 thus supporting the concept of targeting NF-κB as antitumor strategy. In this paper, we demonstrate that although CD99 co-operates with EWS-FLI1 to sustain EWS malignancy, 19 it contrasts EWS-FLI1 for maintaining active NF-κB. Indeed, we show that EWS-FLI1 has a negative influence on NF-κB basal activity, in line with a previous report showing EWS-FLI1 impairing TNFα-induced NF-κB-driven transcription, partly through inhibition of NF-κB binding to DNA. 53 We also show that silencing CD99 in human EWS cell lines reduces NF-κB signaling regardless of 
CD99 regulates EWS differentiation through NF-κB inhibition S Ventura et al
whether EWS-FLI1 is either active or silenced and oriented the cells toward a terminal neural differentiation. This is particularly important because other studies have suggested that EWS-FLI1 itself induces neural differentiation in a variety of cellular contexts 54 and that CD99 participates in the transformed phenotype by preventing neural differentiation of EWS cells. 19 Here we unveil the role of NF-κB in blocking the terminal differentiation. This effect may result from a direct activity of NF-κB in controlling proliferation and differentiation of neural stem cells, 55, 56 or from indirect mechanisms due to a physical interaction between NF-κB and EWS-FLI1. 53 NF-κB activation promotes osteogenesis in human mesenchymal stem cells 57 or in adipose tissue-derived stromal cells. 58 In contrast, EWS-FLI1 expression in murine mesenchymal stem cells blocked their differentiation into osteocytic or adipocytic lineages in favor of neural differentiation. 33 It might be possible that the interaction between these two transcription factors contribute to the maintenance of an undifferentiated state of the EWS cells through reciprocal impairment. Silencing of CD99 by abolishing NF-κB signaling led to unrestricted EWS-FLI1 activity, which may drive EWS cells toward neural differentiation. Our previous study has also shown how EWS-FLI1 and CD99 display opposite effects with respect to mitogen-activated protein kinase pathway. 19 In particular, silencing of CD99 prolonged nuclear extracellular signal-regulated protein kinases 1 and 2 phosphorylation and this seems to be crucial for shifting the biological functions of extracellular signalregulated protein kinases 1 and 2 toward neural differentiation. This suggests a model according to which EWS-FLI1 and CD99 have opposite effects with respect to several crucial transcriptional factors. Suppression of CD99 may thus serve to fine-tune levels of transcriptional gene regulation, shifting the equilibrium in favor of cell differentiation rather than proliferation. Further studies are required to test the functional cross-talk between EWS-FLI1 and extracellular signal-regulated protein kinases 1 and 2 in the absence of NF-κB.
Among the transcriptional regulators of NF-κB there is the Notch pathway, another major cell fate regulatory network. Multiple cross-talk mechanisms between Notch and NF-κB in CD99 regulates EWS differentiation through NF-κB inhibition S Ventura et al diverse experimental models have been described. 59 Conventional Notch signaling has been reported to be off in EWS. 60, 61 However, the expression of Notch receptors was found to be high either in EWS cell lines or in clinical samples. 61 Thus, Notch may still have a role in EWS cells through noncanonical signaling. In this paper, we indeed suggest that Notch may have an activatory role on NF-κB signaling, as previously described in hippocampal neurons. 62 Of note, Baliko et al. 63 reported that inhibition of Notch induced neural differentiation in two EWS cell lines, without affecting tumor growth in vivo. In our hands, inhibition of Notch pathway by the γ-secretase inhibitor DAPT restrains NF-κB transcriptional activity and increases neural differentiation, thus providing an explanation to the contradictory findings on the presence and the role of Notch signaling in EWS. Moreover, EWS cells deprived of CD99 showed diminished expression of Notch 1 and 3, as well as of their downstream target HEY-1. We provide evidence that this effect could be miR-34a-mediated. Notch 1 and other components of the pathway are, in fact, validated targets of miR-34a. 64 We show that the level of miR-34a is higher in CD99-silenced cells and that miR-34a mimic can both reduce Notch 1 and NF-κB and it increases neural differentiation of EWS cells. The same outcome was obtained by exposing EWS cells to exosomes derived from cells silenced for CD99. Exosomes are small vesicles (40-130 nm), naturally produced by many cell types, that entrap key elements necessary for intercellular communication. They are emerging as crucial messengers that can regulate physiological and pathological processes through the delivery of their content to recipient cells. 65 The composition of exosomes is related to their site of CD99 regulates EWS differentiation through NF-κB inhibition S Ventura et al biogenesis. Owing to their endosomal origin, all exosomes showed an enrichment of certain protein families such as Rab GTPases, heat-shock proteins, tetraspanins and MVB biogenesis proteins. CD99 can directly interact and form complex with tetraspanin CD81, 66 a well-characterized exosomal marker. Exosomes released by CD99-silenced EWS cells contain levels of miR-34a higher compared with parental counterpart and successfully downregulate Notch 1 and Notch 3 expression, as well as NF-κB transcriptional activity in recipient EWS cells, which in turn differentiate toward a neural phenotype. The composition of exosomes from cells deprived of CD99 is therefore sufficient to induce in recipient parental cells the same phenotype obtained by stable CD99 silencing. Confirming the sequential path miR-34a/ Notch/NF-κB that follows CD99 silencing, our results suggest that exosomes released from CD99-silenced EWS cells have the capacity to interfere with the fate of human EWS cells. A schematic representation of the molecular mechanisms associating CD99 deprivation with neural differentiation of EWS cells is shown ( Figure 6 ). Our findings indicate that EWS patients may benefit from combinations of agents targeting both Notch and NF-κB pathways. Furthermore, exosome-mediated diffusion of the effects initiated by CD99 abrogation suggests that even partial delivery of CD99 small interfering RNA (siRNA) may have a broad effect on the entire tumor cell population, a feature that can be exploited for therapeutic application.
MATERIALS AND METHODS

Cell lines
Patient-derived EWS cell lines were grown as described previously.
19
ASP14 cell line, a stable cell line generated from A673 EWS cell line transfected with doxycyclin-inducible shRNA targeting EWS-FLI1 67 was cultured in complete medium supplemented with 20 μg/ml blasticidin (Invitrogen, Grand Island, NY, USA) and 50 μg/ml zeocin (Sigma-Aldrich, St Louis, MO, USA). Stable silencing of CD99 was obtained in TC-71 19 and IOR/CAR EWS cell lines (Supplementary Figure 1) . TC-CTR-shRNA cells and TC-CD99-shRNA clones were established and cultured as described previously. 19 CAR-CTR-shRNA and CAR-CD99-shRNA clones were maintained in complete medium supplemented with 1000 μg/ml G418 disulfate salt (Sigma-Aldrich). C3H1OT1/2 murine mesenchymal cells transfected with EWS-FLI1 (C3H1OT1/2 EF) and with CD99 (C3H1OT1/2 EF-CD99) were cultured as described previously. 19 TC-71 cells stably expressing miR-34a (TCpMIF miR-34a) were obtained by infection with the feline immunodeficiency lentivirus-based construct pMIF-cGFPZeo-miR-34a (System Biosciences, Mountain View, CA, USA), as described previously. 68 Empty lentivirus (pMIF-cGFPZeo EV) was used as a control; cells were selected with 100 μg/ml zeocin (Sigma-Aldrich) before performing functional studies (Supplementary Figure 5) . All cell lines were tested for mycoplasma contamination every 3 months by MycoAlert Mycoplasma Detection Kit (Lonza, Allendale, NJ, USA) and were recently authenticated by short tandem repeat-PCR analysis using genRESVR MPX-2 and genRESVR MPX-3 Kits (Serac, Bad Homburg, Germany). The following loci were verified: D16S539, D18S51, D19S433, D21S11, D2S1338, D3S1358, D5S818, D8S1179, FGA, SE33, TH01 and TPOX VWA.
Plasmid and gene transfection
For stable silencing of CD99, an shRNA plasmid (pSilencer 2.1-U6 Neo vector; Ambion, Grand Island, NY, USA) expressing CD99 siRNA-1 was transfected in IOR/CAR cell line as reported previously. 19 Transient suppression of CD99 was performed by using siRNA-CD99 (Ambion) sense strand 5′-GGCUGGCCAUUAUUAAGUCTT-3′ and antisense strand 5′-GACUUAAUAAUGGCCAGCCTT-3′; ON-TARGETplus Non-Targeting siRNAs was used as a control (GE Healthcare, Piscataway, NJ, USA). Transient silencing of EWS-FLI1 was performed with siRNA sequences for EWS-FLI1-specific EF30. 60 Stable silencing of NF-κBp65 was obtained with plasmid shNF-κBp65(a), kindly provided by Dr Johannes Schmid, University of Vienna (Wien, Austria). Transient overexpression of NF-κBp65 was induced by pCMVp65 construct (obtained from Prof. Alain Israel, Departement de Biologie Cellulaire et Infection, Institute Pasteur, Paris, France). Plasmids and siRNAs were transfected into cells by Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Cells were transfected with miR-34a mimics and nonspecific control miRNAs (Applied Biosystem, Grand Island, NY, USA; assay nos. AM17101 and AM17110) 24 h after cell seeding as described previously. 
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Immunoblot analysis
Western blotting experiments were performed as described previously. 19 The following antibodies were used: anti-Actin (Millipore, Billerica, MA, USA; cat. no. MAB1501); anti-CD99 (sc-53148), anti-Delta (sc-9102), anti-Delta-3 (sc-67270), anti-FLI1 (sc-356), anti-GAPDH (sc-25778), antiLamin-B (sc-6216), anti-NF-κBp65 (sc-372), anti-Notch 1 (sc-6014_R) and anti-Notch 3 (sc-5593) (Santa Cruz Biotechnology, Dallas, TX, USA); antiphospho-NF-κBp65 (Ser536) (Cell Signaling Technology, Beverly, MA, USA; cat. no. 3031); and anti-α-Tubulin (Sigma-Aldrich; cat. no. T5168). Antirabbit or anti-mouse antibodies conjugated to horseradish peroxidase (GE Healthcare; cat. nos NA934V and NA931V) were used as secondary antibodies. Proteins were visualized by incubating with ECL (EuroClone, Milan, Italy).
Immunofluorescence analysis
Immunofluorescence was performed on adherent cells grown on coverslips for 72 h and fixed in 4% paraformaldehyde or in methanol/acetone 3:7, and permeabilized with 0.15% Triton X-100 in phosphate-buffered saline, and incubated with the following antibodies: anti-β-III Tubulin (Sigma-Aldrich; cat. no. T5076), anti-NF-H (Cell Signaling Technology; cat. no. 2836) and anti-NF-κBp65 (Santa Cruz Biotechnology; cat. no. sc-372). Nuclei were counterstained by bisbenzimide Hoechst 33258 (SigmaAldrich). Cell fluorescence was then evaluated by microscope Nikon Eclipse 90i (Nikon Instruments, Firenze, Italy).
Luciferase assay
A total of 30 000 cells per well were plated in triplicate and grown for 24 h before transfection in a 24-well plate coated with 3 μg/cm 2 fibronectin (Sigma-Aldrich). Cells were transfected with 50 ng of the appropriate following responsive reporter: IgκB-conA-luciferase, conA-luciferase (all obtained from Prof. Alain Israel, Departement de Biologie Cellulaire et Infection); pRL-TK (Promega, Madison, WI, USA); SRE, E2F, CREB and AP1 cignal reporters (Qiagen, Hilden, Germany) by Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Firefly luciferase activity was normalized to that of Renilla luciferase included as an internal control. Luciferase activity was measured by the Dual-Glo Luciferase Assay System (Promega) according to the manufacturer's protocol with a GloMax-Multi+ Microplate Multimode Reader (Promega). When indicated, cells were treated with 1 ng/ml TNFα (Sigma-Aldrich) 4 h before measuring luciferase signal. When luciferase assays were performed in the presence of exosomes, 20 000 cells per well were plated and grown as reported before. Then, the cells were transfected with 200 ng of the appropriate responsive reporter (IgκB-conA-luciferase, conA-luciferase, pRL-TK) by using Lipofectamine 2000 according to the manufacturer's protocol. After 24 h, the same amounts of control (CTR) or CD99-null purified exosomes were incubated with recipient cells for 30 min at 37°C before performing luciferase assay.
Neural differentiation EWS cells were seeded at low density (30 000/dish 60 mm) in a standard medium. After 72 h, immunofluorescence analysis was carried out to stain the markers of neurons (β-III Tubulin and neurofilament-H).
DAPT treatment EWS cells were treated with dimethyl sulfoxide (Sigma-Aldrich) carrier alone or the γ-secretase inhibitor DAPT (Selleck Chemicals, Houston, TX, USA) at 2.5 μM for 48 h.
RNA extraction, PCR and quantitative real-time PCR analysis
Total RNA was extracted by TRIzol (Invitrogen) following the manufacturer's instructions. Reverse transcription, PCR amplification and 1% agarose gel electrophoresis were carried out according to standard protocols. Primer pair sequences used for PCR amplifications were as follows: (C-Rel sense: 5′-TTGAAGACTGCGACCTCAATG-3′ and antisense: 5′-GGGGCACGGTTATCATAAATTGG-3′; RelB sense: 5′-TGATGTCCTTGGA GAGTTGAG-3′ and antisense: 5′-GCAGGTCCAACATAGTGAAGA-3′; RelA sense: 5′-AGCCTCCAGCCCCAGTGAAG-3′ and antisense: 5′-CTCGGT AAAGCTGAGTTTGCG-3′; NF-kB1 sense: 5′-TCCACTGTCTGCCTCTCTCGTC-3′ and antisense: 5′-GCCTTCAATAGGTCCTTCCTGC-3′; NF-kB2 sense: 5′-TCCA CCTTTAAGTTGCCCTG-3′ and antisense: 5′-TCTGCTCTCGTCATGTCACC-3′; β-actin sense: 5′-GCCGGGAAATCGTGCGTG-3′, antisense: 5′-GGGTACATG GTGGTGCCG-3′). Quantitative real-time PCR was performed on ABI Prism 7900 (Applied Biosystems) using TaqMan HEY-1 assay (Applied Biosystems; cat. no. Hs00232618_m1) as reported previously. 69 Primer Express software (Applied Biosystems) was used to design appropriate primer pairs for reference gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase). 69 Quantitative real-time PCR analysis of miR-34a was performed using a TaqMan miRNAassay Kit (Applied Biosystems) as described previously. 39 Two replicates were considered. Relative quantification analysis was performed on ΔΔCt method. 70 Exosome isolation, characterization and functional assays Exosomes (EXO) were isolated from 24 h cell culture media by ultracentrifugation or Exoquick-TC (System Biosciences) methods according to the standard procedures or the manufacturer's instruction, with minor modifications. For exosome purification, serum was depleted of bovine exosomes by ultracentrifugation at 100 000 g for 6 h, followed by passing it through 0.2 μm filter before use. EXO protein concentration was determined using a Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA, USA). RNA was isolated from exosomes using the 'Total RNA Purification Micro Kit' (NorgenBioteK Corp, Thorold, ON Canada) and analyzed by quantitative real-time PCR for miR-34a and miR-16 (Applied Biosystems; assay nos 000426 and 000391, respectively). Expression of miR-16 was used for normalizing secreted miRNAs as described previously. 71, 72 For western blot analysis, exosome samples were lysed in buffer (0.5% Triton; 300 mM NaCl; 50 mM Tris-NaCl) supplemented with protease inhibitor cocktail. Antibodies listed below were used in accordance to the manufacturer's instructions: RAB5B (Santa Cruz Biotechnology; cat. no. sc-598); CD63 (cat. no. EXOAB_CD63A-1) and CD81 (cat. no. EXOAB_CD81A-1) from System Biosciences. The expression levels were evaluated by the AlphaView (ProteinSimple, San Jose, CA, USA) or Image Quant Software (GE Healthcare). For in vitro experimental model of fusion, the same amounts of exosomes, either purified from parental or CD99-shRNA EWS cell lines, were incubated with recipient cells for 24 h at 37°C before performing expression studies and functional assays. Exosome-induced differentiation was evaluated by immunofluorescence after 3 days of culture in low serum condition.
Statistics
Differences among means were analyzed using two-tailed Student's t-test. Differences were considered significant if P-values were o 0.05 (*) and o0.01 (**).
